Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93063 | 0.82 | S1PR1 (0.51) | S1PR1ALDH1A1RECQLSMN1; SMN2TTR | |
| SCHEMBL31533145 | 0.82 | S1PR1 (0.51) | S1PR1ALDH1A1RECQLSMN1; SMN2TTR | |
| SCHEMBL12107538 | 0.81 | CYP3A4 (0.54) | CYP3A4ALDH1A1NPSR1KDM4ECCR2 | |
| SCHEMBL82284 | 0.79 | IGF1R (0.44) | S1PR1CYP3A4ALDH1A1NPSR1KDM4E | |
| SCHEMBL30031076 | 0.79 | CYP3A4 (0.48) | CYP3A4ALDH1A1NPSR1KDM4ECCR2 | |
| SCHEMBL1755262 | 0.79 | MAPT (0.49) | S1PR1CYP3A4ALDH1A1NPSR1KDM4E | |
| SCHEMBL4026046 | 0.79 | CYP3A4 (0.48) | CYP3A4ALDH1A1NPSR1KDM4ECCR2 | |
| SCHEMBL93048 | 0.78 | S1PR1 (0.47) | S1PR1CYP3A4ALDH1A1RECQLGAA | |
| SCHEMBL92905 | 0.78 | IDO1 (0.58) | S1PR1RECQLSMN1; SMN2HSD17B10 | |
| SCHEMBL109221 | 0.77 | CYP3A4 (0.52) | CYP3A4ALDH1A1NPSR1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-07-03 | — | — | US | disclosed |
| CN-119585252-A | Bicyclic heteroaryl containing compounds as IKZF2 degrading agents | 翁科皮亚治疗公司和SK生命科学实验室 | 2025-03-07 | — | — | CN | disclosed |
| EP-4499629-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4444697-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4442319-A2 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| CN-118632834-A | Indanyl compounds containing carboxylic acids for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4081511-B1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7060721-B1 | Imidazole compounds and medicinal use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-06-13 | — | — | US | disclosed |
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1142879-A1 | IMIDAZOLE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| CN-1268942-A | Sulfonamide compounds and medicinal use thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-10-04 | — | — | CN | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | S1PR1 215/4885CYP3A4 2770/4885ALDH1A1 570/4885 |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | S1PR1 58/4885CYP3A4 573/4885ALDH1A1 2888/4885 |
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, S1PR2, LPAR5 | S1PR1 4/4885CYP3A4 3913/4885ALDH1A1 766/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | S1PR1 1171/4885CYP3A4 1979/4885ALDH1A1 1067/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | S1PR1 1855/4885CYP3A4 2474/4885ALDH1A1 339/4885 |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | IKZF1, IKZF2, IKZF3 | S1PR1 4671/4885CYP3A4 308/4885ALDH1A1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.